NovaDigm Therapeutics Closes $14M Series B Financing

NovaDigm Therapeutics, a Grand Forks, North Dakota-based developer of vaccines for fungal and bacterial infections, closed a $14m Series B financing.

Backers included new investor RusnanoMedInvest and current investor Domain Associates.

Led by Timothy Cooke, Ph.D., Chief Executive Officer, NovaDigm is developing NDV-3, a vaccine being developed for the treatment and prevention of infections caused by several species of the fungus Candida, including Candida albicans (yeast), and the bacterium Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus, or MRSA).

The company intends to use the funds to conduct an ongoing Phase 2 clinical trial of NDV-3 as well as to pursue the development of additional antigens to be used in vaccines against Candida.



Join the discussion